-transparent.png){kind=logo}
We examined the effects of TCV-116, a non-peptide selective AT1 receptor antagonist, on cellular phenotype and on the expression of the transforming growth factor-beta 1 (TGF-beta 1) and extracellular matrix genes in the kidneys of stroke-prone spontaneously hypertensive rats (SHRSP). SHRSP were given vehicle or TCV-116 (10 mg/kg/day) by gastric gavage for 10 weeks (from the age of 22 to 32 weeks). Renal mRNA levels were measured by Northern blot analysis. In vehicle-treated 32-week-old SHRSP, urinary albumin excretion per 24 h was about 26-fold greater than that in age-matched Wistar-Kyoto (WKY) rats, and the mRNA levels of renal TGF-beta 1, fibronectin and collagen types I and III in SHRSP were all several-fold higher than those in WKY. Immunohistochemical studies showed the prominent presence of alpha-smooth muscle actin-expressing glomerular cells in SHRSP, in contrast to their absence in WKY. Treatment of SHRSP with TCV-116 decreased urinary albumin excretion and renal mRNA levels for TGF-beta 1 and for the above-mentioned extracellular matrix components. TCV-116 prevented the phenotypic modulation of glomerular cells in SHRSP. These results suggest that AT1 receptor antagonists may have powerful renal protective effects.
S Kim, and
K Ohta, and
A Hamaguchi, and
T Omura, and
T Yukimura, and
K Miura, and
Y Inada, and
T Wada, and
Y Ishimura, and
F Chatani
October 1997,
Clinical and experimental hypertension (New York, N.Y. : 1993),
S Kim, and
K Ohta, and
A Hamaguchi, and
T Omura, and
T Yukimura, and
K Miura, and
Y Inada, and
T Wada, and
Y Ishimura, and
F Chatani
June 2010,
European journal of pharmacology,
S Kim, and
K Ohta, and
A Hamaguchi, and
T Omura, and
T Yukimura, and
K Miura, and
Y Inada, and
T Wada, and
Y Ishimura, and
F Chatani
June 2004,
Hypertension research : official journal of the Japanese Society of Hypertension,
S Kim, and
K Ohta, and
A Hamaguchi, and
T Omura, and
T Yukimura, and
K Miura, and
Y Inada, and
T Wada, and
Y Ishimura, and
F Chatani
January 1994,
Blood pressure. Supplement,
S Kim, and
K Ohta, and
A Hamaguchi, and
T Omura, and
T Yukimura, and
K Miura, and
Y Inada, and
T Wada, and
Y Ishimura, and
F Chatani
September 1982,
European journal of pharmacology,
S Kim, and
K Ohta, and
A Hamaguchi, and
T Omura, and
T Yukimura, and
K Miura, and
Y Inada, and
T Wada, and
Y Ishimura, and
F Chatani
December 1995,
Clinical and experimental pharmacology & physiology. Supplement,
S Kim, and
K Ohta, and
A Hamaguchi, and
T Omura, and
T Yukimura, and
K Miura, and
Y Inada, and
T Wada, and
Y Ishimura, and
F Chatani
April 2008,
The British journal of nutrition,
S Kim, and
K Ohta, and
A Hamaguchi, and
T Omura, and
T Yukimura, and
K Miura, and
Y Inada, and
T Wada, and
Y Ishimura, and
F Chatani
April 1975,
Nihon eiseigaku zasshi. Japanese journal of hygiene,
S Kim, and
K Ohta, and
A Hamaguchi, and
T Omura, and
T Yukimura, and
K Miura, and
Y Inada, and
T Wada, and
Y Ishimura, and
F Chatani
May 1996,
Pharmacology,
S Kim, and
K Ohta, and
A Hamaguchi, and
T Omura, and
T Yukimura, and
K Miura, and
Y Inada, and
T Wada, and
Y Ishimura, and
F Chatani
May 2007,
Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association,
